The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
about
sameAs
Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCRThe neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulationStructures of the extracellular regions of the group II/III metabotropic glutamate receptorsMolecular targets for antiepileptic drug developmentNeuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsStructure and ligand recognition of class C GPCRsCharacterization of a truncated metabotropic glutamate receptor in a primitive metazoan, the parasitic flatworm Schistosoma mansoniThe heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptorGroup I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation.Design and synthesis of substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides as positive allosteric modulators of the metabotropic glutamate receptor subtype 5.Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.Potentiation of Excitotoxicity in HIV-1 Associated Dementia and the Significance of Glutaminase.Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade.Ion channels and signaling in the pituitary gland.Activation of group II metabotropic glutamate receptors inhibits glutamatergic transmission in the rat entorhinal cortex via reduction of glutamate release probability.Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems.Innovative approaches for the development of antidepressant drugs: current and future strategiesEstimation of ligand efficacies of metabotropic glutamate receptors from conformational forces obtained from molecular dynamics simulations.Activation of synaptic group II metabotropic glutamate receptors induces long-term depression at GABAergic synapses in CNS neurons.Radiosynthesis of N-(4-chloro-3-[(11)C]methoxyphenyl)-2-picolinamide ([(11)C]ML128) as a PET radiotracer for metabotropic glutamate receptor subtype 4 (mGlu4).Metabotropic glutamate receptor ligands as potential therapeutics for addictionSynthesis and evaluation in monkey of [(18)F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([(18)F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1)Olfactory receptor surface expression is driven by association with the beta2-adrenergic receptor.Glutamate receptors as therapeutic targets for Parkinson's disease.Metabotropic glutamate receptor subtype 5 antagonism in learning and memory.Recent progress on the identification of metabotropic glutamate 4 receptor ligands and their potential utility as CNS therapeutics.The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatmentProgesterone potentiates calcium release through IP3 receptors by an Akt-mediated mechanism in hippocampal neurons.Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP.Opposite effects of Zn on the in vitro binding of [3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors.Divergent evolution in metabotropic glutamate receptors. A new receptor activated by an endogenous ligand different from glutamate in insects.Antagonists of Metabotropic Glutamate Receptors Prevent the Development of Audiogenic Seizures.Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand.Heterodimerization and surface localization of G protein coupled receptorsCo-application of the GABAB receptor agonist, baclofen, and the mGlu receptor agonist, L-CCG-I, facilitates [(3)H]GABA release from rat cortical nerve endings.Membrane topology of a metabotropic glutamate receptor.NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR.Correlation between clinical and histologic findings in the human neonatal hippocampus after perinatal asphyxia.Time-resolved fluorescence ligand binding for G protein-coupled receptors.
P2860
Q24556662-AB5D8C09-4A4A-4915-8F74-BED66AFD53C8Q24613593-64E715B0-4640-49E9-BC3E-F9DA37060CE2Q24681315-E4769BC7-978D-4296-8CFF-96A1D67F52FEQ24683346-60D7159D-9267-4EBE-8253-0CF2488B4C4CQ26995351-F2473877-6B58-4622-9523-AEF168B96634Q30486707-AA1EEDB6-EF16-4248-A54A-DB718A8A394BQ33828724-8173A0EB-6BD6-430F-AD7D-BB570B18F96AQ34070596-FE290A7B-DC22-4734-AC9C-0EFD2F1EB191Q34318688-90D35050-4ED2-42DE-9617-3CD2F883E7C0Q34325464-07B06841-5027-4B93-A570-862AB76597BCQ34850993-201A049E-76DB-4AFC-A2A1-4B28B38D67F6Q34975522-BB4EE686-7749-48E9-B144-2452AD1964C8Q35699016-07ADE567-F797-4A58-B3EB-DBE88C852361Q35984134-AA3792D7-328D-408A-86E1-4EE385E2B4C0Q36003349-03C2A68B-DC91-46B1-BE14-70F6516AD199Q36257149-579EF759-9EE7-4BEB-81B1-E1F50305D77FQ36306674-D78308C0-7A8B-42E0-84ED-EFD5DF974A8DQ36401400-ADD7BBB0-E498-455C-AEFD-F3374B502778Q36958036-8A7E6E8D-2182-43FC-B6E3-87C4AC0FB133Q37208500-4F8C615F-B94A-4B26-A1E1-B6B5B076B724Q37265062-539D8CBC-3368-4420-B930-33C15E029B63Q37280041-58356388-54A5-46C3-94BC-0423C063B1FAQ37400392-C10712FC-5A60-4803-82E0-5A230E2DF203Q37535168-254B6ABE-6024-49B9-A7B8-896A7B6889D0Q37585401-4C454768-2A66-4E37-91AB-03F7EF487881Q37723772-D1F19F79-62F5-4465-B23A-E53A5B2411A4Q38031832-80AFF28B-218D-4683-9084-9A80931B4D7AQ38213709-5519399D-E024-4A59-9964-5D71293D41E0Q40221864-2586DB3A-5188-4E69-A96B-812656D50D55Q40262178-CC0EA610-746D-4C1D-9C70-B499FD345444Q40410370-71318EBB-DC3F-4182-91AA-035E71ABB9C2Q40609859-ED02BEDF-A681-4D45-BEB9-1B38CB35743AQ40879782-2E815474-C200-454F-AFD5-988D1061AAF6Q40973806-32F260FA-CDA3-4EE2-92D2-32959FCDB320Q41900573-D79D12F8-554C-4992-9285-016D084AD837Q42440837-9F227A9E-4EB4-4BD1-B799-215A997C65FBQ44452019-EBCC4E1F-767D-46C1-9CAA-860FD03BAB18Q44893918-27776E2D-5FE2-4D0E-BA5A-F1D3298AE731Q46482414-5955688A-8764-49C9-86D5-0BE98CCB1DBAQ46520207-38BD80F9-06AD-4EBC-B01F-A05A5BEC426C
P2860
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@ast
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@en
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@nl
type
label
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@ast
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@en
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@nl
prefLabel
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@ast
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@en
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@nl
P356
P1476
The metabotropic glutamate receptors: structure, activation mechanism and pharmacology
@en
P2093
Francine Acher
P304
P356
10.2174/1568007023339328
P407
P577
2002-06-01T00:00:00Z